The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?

Elvira Stacher, Ulrike Gruber-Mösenbacher, Iris Halbwedl, Angelo Paolo Dei Tos, Alberto Cavazza, Mauro Papotti, Lina Carvalho, Monika Huber, Leander Ermert, Helmut H. Popper

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Malignant epitheloid vascular tumors (epitheloid haemangioendotheliomas and angiosarcomas) of the lung are very rare lesions often posing difficulties in diagnosis. Due to their rare incidence no standardized therapy regimen is established. Surgical resection of the tumor is the mainstay of treatment, but in many cases, especially due to the multifocality of the tumor, negative resection margins cannot be achieved. A blockade of members of the vascular endothelial growth factor (VEGF) system either by antibodies for their ligands or by kinase inhibitors has been increasingly used for the therapy of solid tumors. The aim of our study was to highlight the main distinguishing morphological factors between the two entities for diagnostic purposes. Next, we investigated several factors of the VEGF-signalling pathway as well as Tie 2 in eight primary pulmonary epitheloid haemangioendotheliomas and ten primary pulmonary epitheloid angiosarcomas by means of immunohistochemistry using commercially available antibodies against VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 and endothelium specific kinase Tie2. The observed positivity for the factors of the VEGF-signalling pathway points towards a possible new therapeutic option in the therapy of pulmonary vascular tumors by a blockade of the ligands or their receptors.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalLung Cancer
Volume65
Issue number1
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Hemangioendothelioma
Hemangiosarcoma
Vascular Endothelial Growth Factor A
Lung
Neoplasms
Blood Vessels
Vascular Endothelial Growth Factor B
Phosphotransferases
Vascular Endothelial Growth Factor D
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor C
Ligands
Therapeutics
Vascular Endothelial Growth Factor Receptor-2
Antibodies
Endothelium
Immunohistochemistry
Incidence

Keywords

  • Immunohistochemistry
  • Mesenchymal tumors
  • Pulmonary angiosarcomas
  • Pulmonary haemangioendotheliomas
  • Tie2
  • VEGF
  • VEGFR

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Stacher, E., Gruber-Mösenbacher, U., Halbwedl, I., Dei Tos, A. P., Cavazza, A., Papotti, M., ... Popper, H. H. (2009). The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets? Lung Cancer, 65(1), 49-55. https://doi.org/10.1016/j.lungcan.2008.10.031

The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas : New potential therapeutic targets? / Stacher, Elvira; Gruber-Mösenbacher, Ulrike; Halbwedl, Iris; Dei Tos, Angelo Paolo; Cavazza, Alberto; Papotti, Mauro; Carvalho, Lina; Huber, Monika; Ermert, Leander; Popper, Helmut H.

In: Lung Cancer, Vol. 65, No. 1, 07.2009, p. 49-55.

Research output: Contribution to journalArticle

Stacher, E, Gruber-Mösenbacher, U, Halbwedl, I, Dei Tos, AP, Cavazza, A, Papotti, M, Carvalho, L, Huber, M, Ermert, L & Popper, HH 2009, 'The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?', Lung Cancer, vol. 65, no. 1, pp. 49-55. https://doi.org/10.1016/j.lungcan.2008.10.031
Stacher, Elvira ; Gruber-Mösenbacher, Ulrike ; Halbwedl, Iris ; Dei Tos, Angelo Paolo ; Cavazza, Alberto ; Papotti, Mauro ; Carvalho, Lina ; Huber, Monika ; Ermert, Leander ; Popper, Helmut H. / The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas : New potential therapeutic targets?. In: Lung Cancer. 2009 ; Vol. 65, No. 1. pp. 49-55.
@article{3883779c3eb841b49bfb4a44aca9e36f,
title = "The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets?",
abstract = "Malignant epitheloid vascular tumors (epitheloid haemangioendotheliomas and angiosarcomas) of the lung are very rare lesions often posing difficulties in diagnosis. Due to their rare incidence no standardized therapy regimen is established. Surgical resection of the tumor is the mainstay of treatment, but in many cases, especially due to the multifocality of the tumor, negative resection margins cannot be achieved. A blockade of members of the vascular endothelial growth factor (VEGF) system either by antibodies for their ligands or by kinase inhibitors has been increasingly used for the therapy of solid tumors. The aim of our study was to highlight the main distinguishing morphological factors between the two entities for diagnostic purposes. Next, we investigated several factors of the VEGF-signalling pathway as well as Tie 2 in eight primary pulmonary epitheloid haemangioendotheliomas and ten primary pulmonary epitheloid angiosarcomas by means of immunohistochemistry using commercially available antibodies against VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 and endothelium specific kinase Tie2. The observed positivity for the factors of the VEGF-signalling pathway points towards a possible new therapeutic option in the therapy of pulmonary vascular tumors by a blockade of the ligands or their receptors.",
keywords = "Immunohistochemistry, Mesenchymal tumors, Pulmonary angiosarcomas, Pulmonary haemangioendotheliomas, Tie2, VEGF, VEGFR",
author = "Elvira Stacher and Ulrike Gruber-M{\"o}senbacher and Iris Halbwedl and {Dei Tos}, {Angelo Paolo} and Alberto Cavazza and Mauro Papotti and Lina Carvalho and Monika Huber and Leander Ermert and Popper, {Helmut H.}",
year = "2009",
month = "7",
doi = "10.1016/j.lungcan.2008.10.031",
language = "English",
volume = "65",
pages = "49--55",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas

T2 - New potential therapeutic targets?

AU - Stacher, Elvira

AU - Gruber-Mösenbacher, Ulrike

AU - Halbwedl, Iris

AU - Dei Tos, Angelo Paolo

AU - Cavazza, Alberto

AU - Papotti, Mauro

AU - Carvalho, Lina

AU - Huber, Monika

AU - Ermert, Leander

AU - Popper, Helmut H.

PY - 2009/7

Y1 - 2009/7

N2 - Malignant epitheloid vascular tumors (epitheloid haemangioendotheliomas and angiosarcomas) of the lung are very rare lesions often posing difficulties in diagnosis. Due to their rare incidence no standardized therapy regimen is established. Surgical resection of the tumor is the mainstay of treatment, but in many cases, especially due to the multifocality of the tumor, negative resection margins cannot be achieved. A blockade of members of the vascular endothelial growth factor (VEGF) system either by antibodies for their ligands or by kinase inhibitors has been increasingly used for the therapy of solid tumors. The aim of our study was to highlight the main distinguishing morphological factors between the two entities for diagnostic purposes. Next, we investigated several factors of the VEGF-signalling pathway as well as Tie 2 in eight primary pulmonary epitheloid haemangioendotheliomas and ten primary pulmonary epitheloid angiosarcomas by means of immunohistochemistry using commercially available antibodies against VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 and endothelium specific kinase Tie2. The observed positivity for the factors of the VEGF-signalling pathway points towards a possible new therapeutic option in the therapy of pulmonary vascular tumors by a blockade of the ligands or their receptors.

AB - Malignant epitheloid vascular tumors (epitheloid haemangioendotheliomas and angiosarcomas) of the lung are very rare lesions often posing difficulties in diagnosis. Due to their rare incidence no standardized therapy regimen is established. Surgical resection of the tumor is the mainstay of treatment, but in many cases, especially due to the multifocality of the tumor, negative resection margins cannot be achieved. A blockade of members of the vascular endothelial growth factor (VEGF) system either by antibodies for their ligands or by kinase inhibitors has been increasingly used for the therapy of solid tumors. The aim of our study was to highlight the main distinguishing morphological factors between the two entities for diagnostic purposes. Next, we investigated several factors of the VEGF-signalling pathway as well as Tie 2 in eight primary pulmonary epitheloid haemangioendotheliomas and ten primary pulmonary epitheloid angiosarcomas by means of immunohistochemistry using commercially available antibodies against VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 and endothelium specific kinase Tie2. The observed positivity for the factors of the VEGF-signalling pathway points towards a possible new therapeutic option in the therapy of pulmonary vascular tumors by a blockade of the ligands or their receptors.

KW - Immunohistochemistry

KW - Mesenchymal tumors

KW - Pulmonary angiosarcomas

KW - Pulmonary haemangioendotheliomas

KW - Tie2

KW - VEGF

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=67349175599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349175599&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2008.10.031

DO - 10.1016/j.lungcan.2008.10.031

M3 - Article

C2 - 19100646

AN - SCOPUS:67349175599

VL - 65

SP - 49

EP - 55

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -